Elucidating the Role of Death Receptor 5 in the Heart

阐明死亡受体 5 在心脏中的作用

基本信息

  • 批准号:
    10298879
  • 负责人:
  • 金额:
    $ 38.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-08-01 至 2026-05-31
  • 项目状态:
    未结题

项目摘要

Heart failure is a leading cause of morbidity and mortality worldwide. Cardiomyocyte survival and death play a crucial role in the pathogenesis of heart failure due to the limited capacity of cardiomyocytes to proliferate or repair. Recently, multiple clinical studies have identified TNF-related apoptosis inducing ligand (TRAIL) and its receptor, death receptor 5 (DR5), as being two of the most powerful predictive markers of heart failure development and severity. Additionally, whole transcriptome analysis from our laboratory identified TRAIL and DR5 alterations in a mouse model of heart failure and its involvement in cardioprotective, EGFR-dependent signaling. While there have been multiple studies demonstrating high expression of TRAIL and DR5 in the heart, their function has never been investigated. The role of TRAIL/DR5 in cancer has been extensively studied due to the ability of TRAIL to selective induce apoptosis in cancer cells, however, in non-transformed cell types, the function of TRAIL/DR5 is unclear. Due to the connection of TRAIL/ DR5 with heart failure and unidentified role of TRAIL/DR5 in the heart we have been exploring the impact of DR5 signaling in cardiomyocytes. Using pharmacological agonists of DR5, we observe that DR5 activation does not induce canonical death receptor signaling pathways in cardiomyocytes but activates the pro-growth and survival kinase ERK1/2. Using specific inhibitors for signal transduction pathways, we observe that ERK1/2 activation involves the transactivation of EGFR and results in cardiomyocyte hypertrophy. Therefore, we hypothesize that DR5 activation in cardiomyocytes plays a non-canonical, cardioprotective role through the activation of pro- growth and survival mechanisms. Completion of the following research proposal will contribute important information to this novel field of study through the identification of the function and signaling mechanisms initiated by DR5 activation in cardiomyocytes, the role of DR5 in the normal and failing heart and the determination of the potential of targeting TRAIL/DR5 as a therapeutic strategy in heart failure.
心力衰竭是世界范围内发病率和死亡率的主要原因。心肌细胞的存活和死亡 由于心肌细胞增殖能力有限, 修复.最近,多项临床研究已经鉴定了TNF相关的凋亡诱导配体(TRAIL)及其受体。 死亡受体5(DR 5)是心力衰竭的两个最有力的预测标志物 发展和严重性。此外,我们实验室的全转录组分析鉴定了TRAIL和 心力衰竭小鼠模型中DR 5的改变及其在心脏保护、EGFR依赖性 发信号。虽然已经有多项研究表明TRAIL和DR 5在肿瘤细胞中的高表达, 心脏,其功能从未被研究过。TRAIL/DR 5在癌症中的作用已被广泛研究。 由于TRAIL在癌细胞中选择性诱导凋亡的能力,然而,在非转化细胞中, 由于细胞类型不同,TRAIL/DR 5的功能尚不清楚。由于TRAIL/DR 5与心力衰竭的联系, TRAIL/DR 5在心脏中的作用尚未确定,我们一直在探索DR 5信号转导在心脏中的影响。 心肌细胞使用DR 5的药理学激动剂,我们观察到DR 5活化不诱导 心肌细胞中典型的死亡受体信号通路,但激活促生长和存活 激酶ERK 1/2。使用信号转导通路的特异性抑制剂,我们观察到ERK 1/2活化 涉及EGFR的反式激活并导致心肌细胞肥大。因此,我们假设 心肌细胞中DR 5的激活通过激活前- 生长和生存机制。完成以下研究计划将有助于 信息,这一新的研究领域,通过识别的功能和信号机制, 在心肌细胞中由DR 5激活启动,DR 5在正常和衰竭心脏中的作用, 确定靶向TRAIL/DR 5作为心力衰竭治疗策略的潜力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Laurel Ann Grisanti其他文献

Laurel Ann Grisanti的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Laurel Ann Grisanti', 18)}}的其他基金

Elucidating the Role of Death Receptor 5 in the Heart
阐明死亡受体 5 在心脏中的作用
  • 批准号:
    10456151
  • 财政年份:
    2021
  • 资助金额:
    $ 38.38万
  • 项目类别:
Elucidating the Role of Death Receptor 5 in the Heart
阐明死亡受体 5 在心脏中的作用
  • 批准号:
    10627963
  • 财政年份:
    2021
  • 资助金额:
    $ 38.38万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 38.38万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 38.38万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 38.38万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.38万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 38.38万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 38.38万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 38.38万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 38.38万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 38.38万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 38.38万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了